Beta Bionics [BBNX] vs Artivion [AORT] Detailed Stock Comparison

Beta Bionics Inc.

NASDAQ
Loading...

Artivion Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Beta Bionics Inc. wins in 4 metrics, Artivion Inc. wins in 14 metrics, with 0 ties. Artivion Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Beta Bionics Inc. Artivion Inc. Better
P/E Ratio (TTM) -6.17 179.71 Artivion Inc.
Price-to-Book Ratio 1.88 4.03 Beta Bionics Inc.
Debt-to-Equity Ratio 2.55 57.67 Beta Bionics Inc.
PEG Ratio 0.13 -1.59 Beta Bionics Inc.
EV/EBITDA -4.20 36.67 Artivion Inc.
Profit Margin (TTM) -60.27% 2.21% Artivion Inc.
Operating Margin (TTM) -87.86% 8.09% Artivion Inc.
EBITDA Margin (TTM) N/A 8.09% N/A
Return on Equity -22.71% 2.70% Artivion Inc.
Return on Assets (TTM) -15.04% 2.34% Artivion Inc.
Free Cash Flow (TTM) $-56.22M $839,000 Artivion Inc.
1-Year Return -29.70% -24.98% Artivion Inc.
Price-to-Sales Ratio (TTM) 4.62 4.15 Artivion Inc.
Enterprise Value $316.73M $1.97B Artivion Inc.
EV/Revenue Ratio 2.87 4.47 Beta Bionics Inc.
Gross Profit Margin (TTM) 59.50% 63.06% Artivion Inc.
Revenue per Share (TTM) $3 $10 Artivion Inc.
Earnings per Share (Diluted) $-1.37 $0.21 Artivion Inc.
Beta (Stock Volatility) N/A 1.62 N/A
Short % of Float 17.13% 4.13% Artivion Inc.

Beta Bionics Inc. vs Artivion Inc. Stock Performance Analysis

Loading Price Chart...

BBNX
AORT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Beta Bionics Inc.-2.66%7.05%21.82%7.61%-59.05%-57.44%
Artivion Inc.0.78%-9.58%-42.08%-46.71%-54.75%-53.71%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Beta Bionics Inc.-29.70%-49.10%-49.10%-49.10%-49.10%-49.10%
Artivion Inc.-24.98%45.13%-23.19%88.21%317.89%366.18%

Performance & Financial Health Analysis: Beta Bionics Inc. vs Artivion Inc.

MetricBBNXAORT
Market Information
Market Cap i$497.75M$1.83B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,578,618273,552
90 Day Avg. Volume i1,188,169406,554
Last Close$12.45$20.58
52 Week Range$8.80 - $32.71$19.16 - $48.25
% from 52W High-61.94%-57.35%
All-Time High$32.71 (Nov 26, 2025)$48.25 (Dec 17, 2025)
% from All-Time High-61.94%-57.35%
Growth Metrics
Quarterly Revenue Growth0.57%0.19%
Quarterly Earnings Growth0.57%0.19%
Financial Health
Profit Margin (TTM) i-0.60%0.02%
Operating Margin (TTM) i-0.88%0.08%
Return on Equity (TTM) i-0.23%0.03%
Debt to Equity (MRQ) i2.5557.67
Cash & Liquidity
Book Value per Share (MRQ)$6.09$9.37
Cash per Share (MRQ)$4.48$1.36
Operating Cash Flow (TTM) i$-54,782,000$39.88M
Levered Free Cash Flow (TTM) i$-44,055,752$-20,097,624
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Beta Bionics Inc. vs Artivion Inc.

MetricBBNX (Apr 26, 2026)AORT (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-6.17179.71
Forward P/E i-5.6732.65
PEG Ratio i0.13-1.59
Price to Sales (TTM) i4.624.15
Price to Book (MRQ) i1.884.03
Market Capitalization
Market Capitalization i$497.75M$1.83B
Enterprise Value i$316.73M$1.97B
Enterprise Value Metrics
Enterprise to Revenue i2.874.47
Enterprise to EBITDA i-4.2036.67
Risk & Other Metrics
Beta iN/A1.62
Book Value per Share (MRQ) i$6.09$9.37

Financial Statements Comparison: Beta Bionics Inc. vs Artivion Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBBNX (2025)AORT (2025)
Revenue/Sales i100.25M441.33M
Cost of Goods Sold i44.71M157.10M
COGS % of Revenue i44.6%35.6%
Gross Profit i55.54M284.23M
Gross Margin i55.4%64.4%
Research & Development i34.79M30.99M
Operating Income (EBIT) i-71.68M26.75M
Operating Margin i-71.5%6.1%
EBITDA i-56.36M59.48M
EBITDA Margin i-56.2%13.5%
Pre-Tax Income i-73.20M14.78M
Pre-Tax Income % of Revenue i-73.0%3.3%
Income Tax iN/A5.01M
Income Tax % of Revenue i0.0%1.1%
Net Income (Profit) i-73.20M9.77M
Profit Margin i-73.0%2.2%

Balance Sheet & Liquidity Metrics

MetricBBNX (2025)AORT (2025)
Cash & Equivalents i31.58M64.91M
Total Current Assets i267.91M358.08M
Total Current Assets % of Revenue i267.2%81.1%
Total Current Liabilities i30.92M101.56M
Total Current Liabilities % of Revenue i30.8%23.0%
Long-Term Debt i5.37M252.24M
Long-Term Debt % of Revenue i5.4%57.2%
Total Shareholders Equity i287.61M448.23M
Retained Earnings i-369.94M-51.50M
Retained Earnings % of Revenue i-369.0%-11.7%
Property, Plant & Equipment i15.87M34.70M

Cash Flow Statement Comparison

MetricBBNX (2025)AORT (2025)
Operating Cash Flow i-66.54M41.11M
Operating Cash Flow % of Revenue i-66.4%9.3%
Capital Expenditures i-5.30MN/A
Free Cash Flow i-56.22M839,000
FCF Margin i-56.1%0.2%
Debt Repayment iN/A-2.46M
Common Stock Repurchase iN/A0

Short Interest & Institutional Ownership Analysis

MetricBBNXAORT
Shares Short i7.60M1.67M
Short Ratio i6.634.28
Short % of Float i17.13%4.13%
Shares Outstanding i44.56M47.84M
Float Shares i23.68M45.40M
% Held by Insiders i0.97%4.52%
% Held by Institutions i109.48%91.48%
% Held by Public i-10.45%4.00%

Dividend Analysis & Yield Comparison: Beta Bionics Inc. vs Artivion Inc.

MetricBBNXAORT
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A